The United States Food and Drug Administration (FDA) has granted approval for a groundbreaking gene-editing treatment for sickle cell disease. In a significant development, the FDA authorized two landmark treatments, Casgevy and Lyfgenia, marking the first approval of cell-based gene therapies for sickle cell disease.
Casgevy, also known as Exa-cel and utilizing the brand name Casgevz, is based on the CRISPR gene-editing tool, a Nobel Prize-winning technology employed to precisely edit patients’ DNA. The approval follows a similar endorsement by Britain’s Medicines and Healthcare Products Regulatory Agency for Casgevy last month.
Sickle cell disease is a rare and life-threatening blood disorder with a considerable unmet medical need. The FDA’s approval is a noteworthy step forward in addressing this condition. Dr. Nicole Verdun of the FDA expressed enthusiasm about advancing the field, particularly for individuals whose lives have been profoundly affected by the disease. The United States Food
In the United States, around 100,000 people are estimated to have sickle cell disease, and globally, over 7.7 million people are affected, primarily those of African or Caribbean descent. The approval of cell-based gene therapies represents a significant stride in the pursuit of more effective and targeted treatments for this debilitating and often life-threatening condition.